Blazing New Trails
in Life Sciences
Leveraging the power of induced pluripotent stem cells (iPSCs) and specialized media, Fujifilm has developed a first-of-its-kind human blood-brain barrier kit* for central nervous system research.
* Research Use Only. Not for diagnostic or therapeutic use.
At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere.
The blood-brain barrier (BBB)’s ability to act as a protective fence between the brain and toxic substances or pathogens in the systemic circulation also presents a formidable challenge to drug discovery and neurological disease research.
FUJIFILM Cellular Dynamics’ newly launched iCell Blood-Brain Barrier Isogenic Kit facilitates mechanistic studies of neurological disease, drug permeability and toxicity, and has the potential to integrate with emerging organ-on-a-chip technologies and other 3D cell culture systems, offering exciting new possibilities for drug discovery and BBB function studies.
See the “Applications of an Isogenic Human iPSC-derived Blood-Brain Barrier (BBB) Model” poster presented at International Society for Stem Cell Research (ISSCR) 2023 for the latest data highlighting the characterization and uses of the iCell BBB Isogenic Kit.
To access, visit: iCell Blood-Brain Barrier Isogenic Kit ISSCR Poster
The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties. The kit consists of FUJIFILM Cellular Dynamics’ human iPSC-derived iCell Brain Microvascular Endothelial Cells, iCell Pericytes, and iCell Astrocytes, as well as specialized culture media, which was jointly optimized with FUJIFILM Irvine Scientific. This BBB kit provides a complete solution for creating complex, 3D cellular models and is available through FUJIFILM Cellular Dynamics. To learn more, visit: iCell Blood-Brain Barrier Isogenic Kit
Fujifilm Life Sciences is comprised of a group of synergistic companies offering products, services and comprehensive solutions that support all stages of therapeutic development, from discovery through commercialization.